First Patient Dosed in Stem Cell Trial for Graft-versus-host Disease – Bioscience Technology
Bioscience Technology |
First Patient Dosed in Stem Cell Trial for Graft-versus-host Disease
Bioscience Technology Australia-based regenerative medicine and stem cell company Cynata Therapeutics Ltd., announced that the first patient has been dosed with the company's mesenchymal stem cell (MSC) therapy in a Phase 1 trial for steroid-resistant acute graft-versus … |
